Woippy, June 12, 2026 at 08:00 CET – ABL Diagnostics (FR001400AHX6 – “ABLD”) announces the conclusion of a multi-year contract with a European pharmaceutical laboratory in the field of neurodegenerative diseases. This contract concerns services operated by CDL Pharma and distributed by ABL Diagnostics.
This partnership is part of an international clinical program involving 30 centers spread across 11 countries in North America, Europe and Asia, reflecting the Group’s capacity to intervene in multicenter studies on a global scale.
The agreement provides for an initial payment of more than €100,000 upon signature as well as a total contractual amount of up to approximately €2.7 million until 2031. Revenues will be recognized progressively based on the execution of the services provided for in the contract and remain dependent on the actual progress of the clinical program.
In this context, CDL Pharma will provide specialized services covering the operational management of international clinical trials, logistics and transport of biological samples, design and management of sampling kits, cryobiological storage as well as biomarker analyses. ABL Diagnostics acts as a distributor of these services to the end customer.
